International Journal of Clinical and Experimental Physiology

ORIGINAL ARTICLE
Year
: 2018  |  Volume : 5  |  Issue : 2  |  Page : 70--74

Persistence of oxidative stress in newly diagnosed hypothyroid patients despite effective thyroxin therapy


Nivedita Nanda1, Zachariah Bobby1, Abdoul Hamide2 
1 Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
2 Department of Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India

Correspondence Address:
Dr. Zachariah Bobby
Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry - 605 006
India

Background and Aim: We have earlier reported increased oxidative stress (OS) in newly diagnosed hypothyroid patients. However, the comprehensive effect of thyroxin supplementation on OS, insulin resistance, inflammation, and glycation levels has not been analyzed. Therefore, in the present study, we have analyzed the effect of thyroxin therapy in newly diagnosed hypothyroid patients on OS and various biochemical markers after normalization of thyroid profile. Methods: Out of 67 recently diagnosed primary hypothyroid patients, 37 patients were recruited for this study based on the criteria of strict adherence to thyroxin treatment protocol and regular follow-up. Venous blood samples were analyzed before and 6 months after initiation of therapy for glucose, thyroid and lipid profiles, insulin, ultrasensitive C-reactive protein (usCRP), and anti-thyroperoxidase (TPO) antibody. Antioxidants such as glutathione, glutathione peroxidase, catalase, and glutathione S-transferase, and oxidized products such as malondialdehyde (MDA), and protein carbonyl (PCO) levels were analyzed as parameters of OS. HbA1 and fructosamine were assayed as glycation indices, and lipid risk factor for coronary artery disease was calculated from lipid profile. The parameters were re-assayed 6 months later after normalization of thyroid profile. Results: OS (MDA; P < 0.01 and PCO; P < 0.01) did not come back to normal level despite attainment of normal thyroid profile following treatment. Dyslipidemia (P < 0.05) and inflammation (P < 0.05) were significantly associated with OS. Furthermore, levels of triglyceride, anti-TPO antibody, and usCRP were higher in patients even after successful treatment. Conclusion: OS in treated hypothyroid patients despite normalization of thyroid profile persists longer which could partly be due to the residual inflammation and/or dyslipidemia.


How to cite this article:
Nanda N, Bobby Z, Hamide A. Persistence of oxidative stress in newly diagnosed hypothyroid patients despite effective thyroxin therapy.Int J Clin Exp Physiol 2018;5:70-74


How to cite this URL:
Nanda N, Bobby Z, Hamide A. Persistence of oxidative stress in newly diagnosed hypothyroid patients despite effective thyroxin therapy. Int J Clin Exp Physiol [serial online] 2018 [cited 2019 Mar 26 ];5:70-74
Available from: http://www.ijcep.org/article.asp?issn=2348-8832;year=2018;volume=5;issue=2;spage=70;epage=74;aulast=Nanda;type=0